Drug Trial Radar · NCT04625907
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Last checked: Nov 19, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,672
Planned (sponsor's estimate)
Start
Sep 17, 2020
Primary completion
Jun 2030
Study completion Jun 2030
Sponsor
- Lead sponsor
- University of BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
Conditions
- Rhabdomyosarcoma
Interventions
IrinotecanDrug
antineoplastic enzyme inhibitor
Actinomycin DDrug
Antineoplastic agent that is a polypeptide antibiotic
DoxorubicinDrug
An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius
IfosfamideDrug
chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide
VincristineDrug
anti neoplastic vinca alkaloid agent
VinorelbineDrug
vinca alkaloid with a role as an antineoplastic agent
CyclophosphamideDrug
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent
TemozolomideDrug
oral antineoplastic alkylating agent
radiotherapyRadiation
Ionising radiation
RegorafenibDrug
Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event Free Survival (RT2)Time frame: From randomisation to first failure event, timeframe 36 months
- Event Free Survival (CT1A)Time frame: From randomisation to first failure event, timeframe 36 months
- Event Free Survival (CT1B)Time frame: From randomisation to first failure event, timeframe 36 months
- Event Free Survival (CT2A)Time frame: From randomisation to first failure event, timeframe 36 months
- Event Free Survival (CT2B)Time frame: Time from randomisation to first failure event, timeframe 36 months
- Event Free Survival (CT3)Time frame: Patients will be followed up for a minimum of 6 years from trial entry (or 5 years from end of relapsed trial treatment, whichever comes later). Patients will be followed up for progression and death until the end of trial definition has been met.
- Local Failure Free Survival (RT1A and RT1B)Time frame: Time from randomisation to first local failure event, timeframe 36 months
- Local Failure Free Survival (RT1C)Time frame: Time from randomisation to first local failure event, timeframe 36 months
Locations
128 sites in 20 countries. Site status is shown where the registry gives one.
Queensland Children's Hospital
Brisbane, Australia · Recruiting
Chris O'brien Lifehouse
Camperdown, Australia · Recruiting
Monash Children's Hospital
Clayton, Australia · Recruiting
Peter Maccallum Cancer Centre
Melbourne, Australia · Recruiting
Royal Childrens Hospital Melbourne
Melbourne, Australia · Recruiting
John Hunter Children's Hospital
New Lambton Heights, Australia · Recruiting
Perth Children's Hospital
Perth, Australia · Recruiting
Sydney Children's Hospital
Sydney, Australia · Recruiting
The Childrens Hospital At Westmead
Sydney, Australia · Recruiting
Westmead Hospital
Westmead, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Australia · Recruiting
Kepler University Clinic Linz
Linz, Austria · Recruiting
St Anna Childrens Hospital
Vienna, Austria · Recruiting
Cliniques Universitaires Saint Luc
Brussels, Belgium · Recruiting
Hopital Universitaire Des Enfants Reine Fabiola
Brussels, Belgium · Recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
Uz Leuven Campus Gasthuisberg
Leuven, Belgium · Recruiting
Centre Hospitalier Regional De La Citadelle
Liège, Belgium · Recruiting
Clinique Chc Montlegia
Liège, Belgium · Recruiting
Masaryk University Hospital Brno
Brno, Czechia · Recruiting
Aarhus University Hospital
Aarhus, Denmark · Recruiting
University Hospital Rigshospitalet
Copenhagen, Denmark · Recruiting
Centre Hospitalier Universitaire D'angers
Angers, France · Recruiting
Centre Hospitalier Regional Universitaire Besancon - Hopital Jean Minjoz
Besançon, France · Recruiting
Centre Hospitalier Universitaire De Bordeaux - Hopital Pellegrin
Bordeaux, France · Recruiting
Centre Hospitalier Regional Universitaire Brest - Hopital Morvan
Brest, France · Recruiting
Centre Francois Baclesse
Caen, France · Recruiting
Centre Hospitalier Universitaire De Caen
Caen, France · Recruiting
Centre Hospitalier Universitaire Dijon Bourgogne - Hopital D'enfants
Dijon, France · Recruiting
Centre Hospitalier Universitaire De Grenoble
Grenoble, France · Recruiting
Centre Hospitalier Universitaire La Reunion
La Réunion, France · Recruiting
Centre Oscar Lambret
Lille, France · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
Hopital De La Timone (ap-hm)
Marseille, France · Recruiting
Centre Hospitalier Universitaire De Nancy
Nancy, France · Recruiting
Centre Hospitalier Universitaire De Nantes
Nantes, France · Recruiting
Hopital Armand Trousseau
Paris, France · Recruiting
Institut Curie
Paris, France · Recruiting
Centre Hospitalier Universitaire Haut Levque
Pessac, France · Recruiting
Centre Hospitalier Universitaire De Poitiers
Poitiers, France · Recruiting
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.